Inspiremd, INC Form 4 insider transactions

Chief Commercial Officer Shane Gleason sold shares of InspireMD common stock to satisfy tax withholding obligations related to restricted stock vesting.

Director Paul Stuka acquired 15,000 shares of InspireMD, Inc. common stock through open market purchases.

CEO and President Marvin Slosman acquired 21,000 shares of InspireMD, Inc. common stock at $1.20 per share.

InspireMD, Inc. Director Paul Stuka has filed an amended Form 4 detailing adjustments to his beneficial ownership of company stock, clarifying previous reporting errors.

Director Paul Stuka purchased 75,626 shares of InspireMD common stock across two transactions in May 2026.

Director Scott R. Ward acquired 89,250 shares of InspireMD, Inc. common stock through open market purchases.

Director Paul Stuka acquired 7,895 shares of InspireMD, Inc. (NSPR) through open market purchases on May 6 and May 7, 2026.

Director Gary S. Roubin acquired 90,000 shares of InspireMD, Inc. common stock at a weighted average price of $1.18.

InspireMD Director Paul Stuka amended a Form 4 to correct the number of common shares purchased on December 9, 2025, at a weighted average price of $1.81.

InspireMD's Chief Commercial Officer sold common stock to cover tax withholding obligations related to restricted stock vesting, not as discretionary trades.

InspireMD, Inc. Director Scott R. Ward was granted 88,053 shares of restricted common stock, vesting on January 14, 2027.

InspireMD's Chief Operating Officer, Andrea Tommasoli, acquired 226,695 shares of common stock, primarily restricted stock, as reported in a recent SEC Form 4 filing.

InspireMD, Inc. Director Paul Stuka was granted 132,076 shares of restricted common stock, vesting in January 2027.

InspireMD's CEO and President, Marvin Slosman, was granted 1,114,792 restricted stock units, vesting over three years.

InspireMD, Inc. Director Gary S. Roubin was granted 88,053 shares of restricted common stock, vesting in January 2027.

InspireMD's Chief Financial Officer, Michael A. Lawless, was granted 226,695 shares of restricted common stock vesting over three years.

InspireMD's Chief Commercial Officer, Shane Gleason, was granted 453,390 shares of restricted common stock, vesting over three years.

InspireMD, Inc. Director Danny L. Dearen received a grant of 44,030 restricted common stock shares, which are set to vest on January 14, 2027.

InspireMD, Inc. director Raymond W. Cohen was granted 44,030 shares of restricted common stock, vesting in January 2027.

InspireMD, Inc. Director Michael Berman was granted 88,053 shares of restricted common stock, vesting on January 14, 2027.

InspireMD Director Kathryn Arnold received an equity grant of 55,556 common shares and 26,276 stock options for services rendered in 2025, preceding her resignation effective December 31, 2025.

InspireMD Director Paul Stuka acquired 5,073 shares of the company's common stock at a weighted average price of $1.81 per share.

InspireMD Director Paul Stuka acquired 5,073 shares of common stock at $1.86 per share, increasing his direct beneficial ownership.

InspireMD Director Paul Stuka acquired 10,130 shares of common stock at $1.85 per share, signaling confidence in the company.

InspireMD, Inc. Director Paul Stuka reported the direct acquisition of 13,431 shares of common stock at $1.62 per share.

InspireMD, Inc. Director Gary S. Roubin was granted 48,000 shares of restricted common stock, vesting on October 7, 2026.

InspireMD, Inc. director Thomas J. Kester received a grant of 37,815 common shares and 19,041 stock options before his resignation effective September 16, 2025.

InspireMD Director Gary Roubin acquired 41,322 shares of common stock at $2.42 per share through a private placement, increasing his beneficial ownership to 608,425 shares.

InspireMD Director Thomas J Kester acquired 30,991 shares of common stock at $2.42 per share through a private placement, increasing his direct beneficial ownership.

InspireMD, Inc. CEO and President Marvin Slosman acquired 10,330 shares of common stock at $2.42 per share through a private placement.